{
  "docId": "019de074-7472-72bc-8651-e49cc0d0319c",
  "docSlug": "c2a880ad0c526527fe8aa49c40270224",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 28,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to highlight the core benefits of the product.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/22",
  "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c",
  "deckJsonHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c.json",
  "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.87,
        "x": 0.07,
        "y": 0.8
      },
      "kind": "callout",
      "text": "AB-161 is advancing into Phase 1 clinical trial in 1H 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "935f2384-92dc-4c91-9794-54c803d63c02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.66,
        "y": 0.26
      },
      "kind": "list",
      "text": "Convenience: Potential for an oral HBsAg reducing agent and all oral combination therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a1ff8bc-f9d8-40c2-bcb4-e9fb7a4de101",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.06,
        "y": 0.26
      },
      "kind": "list",
      "text": "Safety: Next generation small molecule anticipated to circumvent non-clinical safety findings with first generation molecule",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13c458ea-9ba6-4985-b433-40799770a660",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.36,
        "y": 0.26
      },
      "kind": "list",
      "text": "Novelty: Offers a novel mechanism of action to reduce HBsAg, other viral proteins and viral RNA",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7742e35-f2d3-43a3-83f7-140cf9b47a23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "AB-161: Next Generation Oral RNA Destabilizer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cf2e992-2787-4a58-807e-2de82067f70a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "aee335de-f830-483d-9ee2-0cd83c89e8da",
      "evidence": "list/bullet: Safety: Next generation small molecule anticipated to circumvent non-clinical safety findings with first generation molecule",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 8,
      "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 28,
      "from": 17,
      "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 20,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "660159c2-70d4-4fb9-adcd-06670ff0292c",
      "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-101 and AB-161, as potential solutions (p20-22).",
      "position": 1,
      "objective": "What are the key challenges in treating HBV?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}